BRPI0519464A2 - uso de certos compostos fenil-naftila que nço tÊm significante afinidade para er alfa ou beta para proteÇço de neurânios e oligodendràcitos no tratamento de esclerose méltipla - Google Patents

uso de certos compostos fenil-naftila que nço tÊm significante afinidade para er alfa ou beta para proteÇço de neurânios e oligodendràcitos no tratamento de esclerose méltipla

Info

Publication number
BRPI0519464A2
BRPI0519464A2 BRPI0519464-4A BRPI0519464A BRPI0519464A2 BR PI0519464 A2 BRPI0519464 A2 BR PI0519464A2 BR PI0519464 A BRPI0519464 A BR PI0519464A BR PI0519464 A2 BRPI0519464 A2 BR PI0519464A2
Authority
BR
Brazil
Prior art keywords
treatment
alpha
multiple sclerosis
beta
protection
Prior art date
Application number
BRPI0519464-4A
Other languages
English (en)
Inventor
Jean E Merrill
Sandrines Funes
Wayne Petko
Friederike Wirtz-Brugger
Karen Chandross
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0519464A2 publication Critical patent/BRPI0519464A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

USO DE CERTOS COMPOSTOS FENIL-NAFTILA QUE NçO TÊM SIGNIFICANTE AFINIDADE PARA ER ALFA OU BETA PARA PROTEÇçO DE NEURâNIOS E OLIGODENDRàCITOS NO TRATAMENTO DE ESCLEROSE MéLTIPLA. A presente invenção refere-se a um novo uso para certos compostos feniínaftila semelhantes - SERM que não exibem afinidade para receptores de estrogênio (ER) tipo alfa ou beta no tratamento de esclerose múltipla.
BRPI0519464-4A 2004-12-31 2005-12-14 uso de certos compostos fenil-naftila que nço tÊm significante afinidade para er alfa ou beta para proteÇço de neurânios e oligodendràcitos no tratamento de esclerose méltipla BRPI0519464A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64093004P 2004-12-31 2004-12-31
PCT/US2005/045294 WO2006073714A2 (en) 2004-12-31 2005-12-14 Use of certain phenyl-naphthyl compounds that do not have significant affintiy to er alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BRPI0519464A2 true BRPI0519464A2 (pt) 2009-01-27

Family

ID=36647967

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519464-4A BRPI0519464A2 (pt) 2004-12-31 2005-12-14 uso de certos compostos fenil-naftila que nço tÊm significante afinidade para er alfa ou beta para proteÇço de neurânios e oligodendràcitos no tratamento de esclerose méltipla

Country Status (12)

Country Link
US (1) US20070225330A1 (pt)
EP (1) EP1835895A2 (pt)
JP (1) JP2008526742A (pt)
KR (1) KR20070098837A (pt)
CN (1) CN101094664A (pt)
AU (1) AU2005323241A1 (pt)
BR (1) BRPI0519464A2 (pt)
CA (1) CA2593097A1 (pt)
IL (1) IL184228A0 (pt)
MX (1) MX2007006797A (pt)
RU (1) RU2007129150A (pt)
WO (1) WO2006073714A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN103193601A (zh) * 2013-04-11 2013-07-10 山东大学 2-苯基萘衍生物及其在制备抗肿瘤药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2744444B1 (fr) * 1996-02-01 1998-05-29 Roussel Uclaf Nouveaux composes biphenyles, procede et intermediaires de preparation, application a titre de medicaments et compositions pharmaceutiques les renfermant
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents

Also Published As

Publication number Publication date
CA2593097A1 (en) 2006-07-13
AU2005323241A1 (en) 2006-07-13
WO2006073714A2 (en) 2006-07-13
KR20070098837A (ko) 2007-10-05
EP1835895A2 (en) 2007-09-26
US20070225330A1 (en) 2007-09-27
MX2007006797A (es) 2007-08-07
WO2006073714A3 (en) 2007-05-03
JP2008526742A (ja) 2008-07-24
RU2007129150A (ru) 2009-02-10
CN101094664A (zh) 2007-12-26
IL184228A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
BR112012004453A8 (pt) composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
MX2009002496A (es) Combinaciones que contienen un derivado de 4-acilaminopiridina.
GT200600342A (es) Compuestos de cicloalquilo amino-hidantoina y uso de estos para la modulacion de beta-secretasa
BRPI0411528A (pt) uso de isomalte como prebiótico
BR0309606A (pt) Hidrolisados de mercaptosilano bloqueado como agentes de acoplamento para composições elastoméricas carregadas com minerais
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
BRPI0511477A (pt) compostos e composições como moduladores de ppar
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
BRPI0513252A (pt) agente de revestimento de proteção contra corrosão para componentes de metal e processo para a sua preparação
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
ECSP088503A (es) COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS
NI200700250A (es) Moduladores de fenilo y piridilo de lta4h
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.